Cargando…

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review

Denosumab is a potent antiresorptive agent that substantially increases bone mineral density and reduces fracture rates at all skeletal sites for as long as it is administered. However, its favorable skeletal effects reverse quickly upon its discontinuation, because of a vast increase of osteoclast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anastasilakis, Athanasios D., Makras, Polyzois, Yavropoulou, Maria P., Tabacco, Gaia, Naciu, Anda Mihaela, Palermo, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796169/ https://www.ncbi.nlm.nih.gov/pubmed/33406802 http://dx.doi.org/10.3390/jcm10010152

Ejemplares similares

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

The Impact of Antiosteoporotic Drugs on Glucose Metabolism and Fracture Risk in Diabetes: Good or Bad News?
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
por: Anastasilakis, Athanasios D, et al.
Publicado: (2012)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Gender Predilection in Sporadic Parathyroid Adenomas
por: Yavropoulou, Maria P., et al.
Publicado: (2020)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Hypovitaminosis D: Is It Time to Consider the Use of Calcifediol?
por: Cesareo, Roberto, et al.
Publicado: (2019)

Adult Langerhans Cell Histiocytosis and the Skeleton
por: Georgakopoulou, Danae, et al.
Publicado: (2022)

Approach to the management of β thalassemia major associated osteoporosis - a long-standing relationship revisited
por: Yavropoulou, Maria P., et al.
Publicado: (2022)

Bone metabolism in Langerhans cell histiocytosis
por: Anastasilakis, Athanasios D, et al.
Publicado: (2018)

Leg restlessness and hyperparathyroidism in Parkinson's disease, a further clue to RLS pathogenesis?
por: Marano, Massimo, et al.
Publicado: (2023)

Dipeptidyl Peptidase 3 Activity as a Promising Biomarker of Bone Fragility in Postmenopausal Women
por: Menale, Ciro, et al.
Publicado: (2022)

Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature
por: Briganti, Silvia Irina, et al.
Publicado: (2021)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

Efficacy of radiofrequency and laser thermal ablation in solving thyroid nodule-related symptoms and cosmetic concerns. A systematic review and meta-analysis
por: Cesareo, Roberto, et al.
Publicado: (2022)

Real-Time Evaluation of Thyroid Cytology Using New Digital Microscopy Allows for Sample Adequacy Assessment, Morphological Classification, and Supports Molecular Analysis
por: Verri, Martina, et al.
Publicado: (2023)

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation
por: Fu, Qiang, et al.
Publicado: (2023)

Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas
por: Yavropoulou, Maria P, et al.
Publicado: (2020)

A Rare Complication following Thyroid Percutaneous Ethanol Injection: Plummer Adenoma
por: Cesareo, Roberto, et al.
Publicado: (2017)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Hobnail variant of papillary thyroid carcinoma showing goiter-like presentation and rapid growth
por: Naciu, Anda Mihaela, et al.
Publicado: (2021)

Discontinuation of simvastatin leads to a rebound phenomenon and results in immediate peri‐implant bone loss
por: Li, Xianqi, et al.
Publicado: (2016)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

A Rare and Severe Complication Following Thyroid Fine Needle Aspiration: Retropharyngeal Cellulitis
por: Cesareo, Roberto, et al.
Publicado: (2016)

MON-533 Irisin in Post-Menopausal Women with Primary Hyperparathyroidism: An Interplay between Irisin and Pth
por: Palermo, Andrea, et al.
Publicado: (2019)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society
por: Kim, Bu Kyung, et al.
Publicado: (2021)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature
por: Tsourdi, Elena, et al.
Publicado: (2021)

MON-527 Cardiovascular Autonomic Neuropathy As A Cause Of Quality Of Life Impairment In Subjects With Chronic Hypoparathyroidism.
por: Tabacco, Gaia, et al.
Publicado: (2019)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
por: Tay, Wei Lin, et al.
Publicado: (2022)

Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease
por: Anık, Ahmet
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u5e8hllfpjjkke018mt5qrmp57